After years of picking up royalties on GSK’s asthma and COPD inhaler Trelegy, Theravance Biopharma is opting to sell its remaining financial interest to GSK in exchange for a cash reward of $225 million.
Universities, research institutes, and academic centers are powerhouses of innovation in pharmaceuticals and biotechnology, developing novel technologies, drug candidates, and intellectual property (IP) that promise to transform healthcare.
